INHERITED GENETIC SUSCEPTIBILITY TO BREAST CANCER IN PAKISTAN
Breast cancer is a heterogeneous disease. Several genetic, environmental and lifestyle factors are involved in the aetiology of this disease. Genetic risk factors include alterations (mutations) in genes conferring risks to develop breast cancer. Depending on the associated lifetime risks of this malignancy, these genes are categorised into high-, moderate- and low-risk genes. Women carrying mutations in these genes are at an increased risk to develop breast cancer, ovarian cancer and several other malignancies. Breast carcinoma is the most reported malignancy in Pakistani females. Pakistan is a developing country with most of its population living in rural areas; hence, optimal healthcare facilities are inadequate for the early diagnosis and prevention of this disease. Hence, identification of individuals carrying mutations is clinically relevant as different strategies are available for the early detection, risk reduction and better management of this malignancy. This review summarises the findings of the major studies conducted in Pakistan to investigate the contribution of breast cancer predisposing genes. Furthermore, implications of the current studies and future research potentials are discussed.
Key words: Breast cancer gene 1/2, breast cancer, checkpoint kinase 2, genetic susceptibility, Pakistan, RAD51C, tumour Protein p53, Vitamin D receptor
Sasco AJ. Breast cancer and the environment. Horm Res 2003;60 Suppl 3:50.
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86.
Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012. Available from: http://globocan.iarc.fr. [Last cited on 2018 Jan 20]
Aziz Z, Sana S, Saeed S, Akram M. Institution based tumor registry from Punjab: Five year data based analysis. J Pak Med Assoc 2003;53:350-3.
Rashid MU, Muzaffar M, Khan FA, et al. Association between the BSMI polymorphism in the vitamin D receptor gene and breast cancer risk: Results from a Pakistani case control study. PLoS One 2015;10:e0141562.
Rebbeck TR. Inherited genetic predisposition in breast cancer. A population-based perspective. Cancer 1999;86:2493-501.
Apostolou P, Fostira F. Hereditary breast cancer: The era of new susceptibility genes. Biomed Res Int 2013;2013:747318.
Pasche B. Recent advances in breast cancer genetics. Cancer Treat Res 2008;141:1-0.
Pharoah PD, Antoniou A, Bobrow M, et al. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 2002;31:33-6.
Hodgson SV, Morrison PJ, Irving M. Breast cancer genetics: Unsolved questions and open perspectives in an expanding clinical practice. Am J Med Genet C Semin Med Genet 2004;129C:56-64.
Hall JM, Lee MK, Newman B, et al. Linkage of earlyonset familial breast cancer to chromosome 17q21. Science 1990;250:1684-9.
Koonin EV, Altschul SF, Bork P. BRCA1 protein products. Functional motifs. Nat Genet 1996;13:266-8.
Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-92.
Wong AK, Pero R, Ormonde PA, et al. RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2. J Biol Chem 1997;272:31941-4.
Collins N, McManus R, Wooster R, et al. Consistent loss of
the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene 1995;10:1673-5.
Smith SA, Easton DF, Evans DG, et al. Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet 1992;2:128-31.
Schlacher K, Christ N, Siaud N, et al. Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11. Cell 2011;145:529-42.
Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-30.
Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007;25:1329-33.
Mavaddat N, Peock S, Frost D, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: Results from prospective analysis of EMBRACE. J Natl Cancer Inst 2013;105:812-22.
Tai YC, Domchek S, Parmigiani G, et al. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2007;99:1811-4.
Kim H, Choi DH. Distribution of BRCA1 and BRCA2 mutations in Asian patients with breast cancer. J Breast Cancer 2013;16:357-65.
Rashid MU, Zaidi A, Torres D, et al. Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients. Int J Cancer 2006;119:2832-9.
Liede A, Malik IA, Aziz Z, et al. Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan. Am J Hum Genet 2002;71:595-606.
Ahmad J, Le Calvez-Kelm F, Daud S, et al. Detection of BRCA1/2 mutations in breast cancer patients from Thailand and Pakistan. Clin Genet 2012;82:594-8.
Rashid MU, Muhammad N, Amin A, et al. Contribution of BRCA1 large genomic rearrangements to early-onset and familial breast/ovarian cancer in Pakistan. Breast Cancer Res Treat 2017;161:191-201.
Rashid MU, Muhammad N, Bajwa S, et al. High prevalence and predominance of BRCA1 Germline mutations in Pakistani triple-negative breast cancer patients. BMC Cancer 2016;16:673.
Rashid MU, Shah MA, Azhar R, et al. A deleterious BRCA1 mutation in a young Pakistani woman with metaplastic breast carcinoma. Pathol Res
de la Hoya M, Fernández JM, Tosar A, et al. Association between BRCA1 mutations and ratio of female to male births in offspring of families with breast cancer, ovarian cancer, or both. JAMA 2003;290:929-31.
Rashid MU, Torres D, Zaidi A, et al. No association between BRCA mutations and sex ratio in offspring of Pakistani BRCA mutation carriers. Breast Cancer Res Treat 2008;107:155-6.
Rashid MU, Gull S, Faisal S, et al. Identification of the deleterious 2080insA BRCA1 mutation in a male renal cell carcinoma patient from a family with multiple cancer diagnoses from Pakistan. Fam Cancer 2011;10:709-12.
Gowen LC, Johnson BL, Latour AM, et al. Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nat Genet 1996;12:191-4.
Rashid MU, Torres D, Rasheed F, et al. No association of miscarriage and BRCA carrier status in Pakistani breast/ovarian cancer patients with a history of parental consanguinity. Breast Cancer Res Treat 2009;116:211-3.
Rashid MU, Muhammad N, Iqbal K, et al. BRCA1 genetic testing in a Pakistani breast-ovarian cancer family with multiple consanguineous marriages. Clin Genet 2015;88:198-9.
Okorokov AL, Sherman MB, Plisson C, et al. The structure of p53 tumour suppressor protein reveals the basis for its functional plasticity. EMBO J 2006;25:5191-200.
Harris CC. Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996;88:1442-55.
Levine AJ. P53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233-8.
Chompret A, Brugières L, Ronsin M, et al. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer 2000;82:1932-7.
Buyru N, Tigli H, Dalay N. P53 codon 72 polymorphism in breast cancer. Oncol Rep 2003;10:711-4.
Aziz I, Rashid MU, Sultan F, et al. Frequency of pro allele on codon 72 of TP53 in female breast cancer patients of Pakistan: Molecular stress or geography. Pak J Zool 2013;45:1437-46.
Arcand SL, Maugard CM, Ghadirian P, et al. Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families. Breast Cancer Res Treat 2008;108:399-408.
Børresen AL, Andersen TI, Garber J, et al. Screening for germ line TP53 mutations in breast cancer patients. Cancer Res 1992;52:3234-6.
Lalloo F, Varley J, Ellis D, et al. Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. Lancet 2003;361:1101-2.
Rashid MU, Gull S, Asghar K, et al. Prevalence of TP53 germ line mutations in young Pakistani breast cancer patients. Fam Cancer 2012;11:307-11.
Rashid MU, Muhammad N, Faisal S, et al. Constitutional CHEK2 mutations are infrequent in early-onset and familial breast/ovarian cancer patients from Pakistan. BMC Cancer 2013;13:312.
Rashid MU, Muhammad N, Faisal S, et al. Deleterious RAD51C Germline mutations rarely predispose to breast and ovarian cancer in Pakistan. Breast Cancer Res Treat 2014;145:775-84.
Bartek J, Lukas J. Chk1 and chk2 kinases in checkpoint control and cancer. Cancer Cell 2003;3:421-9.
Ahn J, Urist M, Prives C. The chk2 protein kinase. DNA Repair (Amst) 2004;3:1039-47.
Cybulski C, Górski B, Huzarski T, et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 2004;75:1131-5.
Nevanlinna H, Bartek J. The CHEK2 gene and inherited breast cancer susceptibility. Oncogene 2006;25:5912-9.
Cybulski C, Wokołorczyk D, Jakubowska A, et al. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. J Clin Oncol 2011;29:3747-52.
Lee AS, Ang P. CHEK2*1100delC screening of Asian women with a family history of breast cancer is unwarranted. J Clin Oncol 2008;26:2419.
Thirthagiri E, Cheong LS, Yip CH, et al. CHEK2*1100delC does not contribute to risk to breast cancer among Malay, Chinese and Indians in Malaysia. Fam Cancer 2009;8:355-8.
Hollestelle A, Wasielewski M, Martens JW, et al. Discovering moderate-risk breast cancer susceptibility genes. Curr Opin Genet Dev 2010;20:268-76.
Rashid MU, Jakubowska A, Justenhoven C, et al. German populations with infrequent CHEK2*1100delC and minor associations with early-onset and familial breast cancer. Eur J Cancer 2005;41:2896-903.
Choi DH, Cho DY, Lee MH, et al. The CHEK2 1100delC mutation is not present in Korean patients with breast cancer cases tested for BRCA1 and BRCA2 mutation. Breast Cancer Res Treat 2008;112:569-73.
Rajkumar T, Soumittra N, Nancy NK, et al. BRCA1, BRCA2 and CHEK2 (1100 del C) Germline mutations in hereditary breast and ovarian cancer families in South India. Asian Pac J Cancer Prev 2003;4:203-8.
Jalilvand M, Oloomi M, Najafipour R, et al. An association study between CHEK2 gene mutations and susceptibility to breast cancer. Comp Clin Path 2017;26:837-45.
Baloch AH, Daud S, Raheem N, et al. Missense mutations (p.H371Y, p.D438Y) in gene CHEK2 are associated with breast cancer risk in women of Balochistan origin. Mol Biol Rep 2014;41:1103-7.
Vaz F, Hanenberg H, Schuster B, et al. Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet 2010;42:406-9.
Meindl A, Hellebrand H, Wiek C, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet
Sopik V, Akbari MR, Narod SA. Genetic testing for RAD51C mutations: In the clinic and community. Clin Genet 2015;88:303-12.
Thompson ER, Boyle SE, Johnson J, et al. Analysis of RAD51C Germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients. Hum Mutat 2012;33:95-9.
Vuorela M, Pylkäs K, Hartikainen JM, et al. Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility. Breast Cancer Res Treat 2011;130:1003-10.
Pang Z, Yao L, Zhang J, et al. RAD51C Germline mutations in Chinese women with familial breast cancer. Breast Cancer Res Treat 2011;129:1019-20.
Sato K, Koyasu M, Nomura S, et al. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations. Cancer Sci 2017;108:2287-94.
Kiiski JI, Pelttari LM, Khan S, et al. Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer. Proc Natl Acad Sci U S A 2014;111:15172-7.
Rashid MU, Muhammad N, Khan FA, et al. Absence of the FANCM c.5101C>T mutation in BRCA1/2-negative triple-negative breast cancer patients from Pakistan. Breast Cancer Res Treat 2015;152:229-30.
Dorjgochoo T, Delahanty R, Lu W, et al. Common genetic variants in the Vitamin D pathway including genome-wide associated variants are not associated with breast cancer risk among Chinese women. Cancer Epidemiol Biomarkers
Gnagnarella P, Pasquali E, Serrano D, et al. Vitamin D receptor polymorphism fokI and cancer risk: A comprehensive metaanalysis.
Raimondi S, Pasquali E, Gnagnarella P, et al. BsmI polymorphism of vitamin D receptor gene and cancer risk: A comprehensive meta-analysis. Mutat Res 2014;769:17-34.
Yao S, Zirpoli G, Bovbjerg DH, et al. Variants in the vitamin D pathway, serum levels of vitamin D, and estrogen receptor negative breast cancer among African-American women: A case-control study. Breast Cancer Res 2012;14:R58.
Bhattacharjee M, Wientroub S, Vonderhaar BK. Milk protein synthesis by mammary glands of Vitamin D-deficient mice. Endocrinology 1987;121:865-74.
Tang C, Chen N, Wu M, et al. Fok1 polymorphism of
vitamin D receptor gene contributes to breast cancer
susceptibility: A meta-analysis. Breast Cancer Res Treat
Wang J, He Q, Shao YG, et al. Associations between vitamin D receptor polymorphisms and breast cancer risk. Tumour Biol 2013;34:3823-30.
Shahbazi S, Alavi S, Majidzadeh AK, et al. BsmI but not FokI polymorphism of VDR gene is contributed in breast cancer. Med Oncol 2013;30:393.
Iqbal Mu, Khan TA, Maqbool SA. Vitamin D receptor cdx- 2 polymorphism and premenopausal breast cancer risk in southern Pakistani patients. PLoS One 2015;10:e0122657.
Rashid MU, Naeemi H, Muhammad N, et al. A novel deleterious c.2656G>T MSH2 Germline mutation in a Pakistani family with a phenotypic overlap of hereditary breast and ovarian cancer and Lynch syndrome. Hered Cancer Clin Pract 2016;14:14.
Shiovitz S, Korde LA. Genetics of breast cancer: A topic in evolution. Ann Oncol 2015;26:1291-9.
Lohmann K, Klein C. Next generation sequencing and the future of genetic diagnosis. Neurotherapeutics 2014;11:699-707.
Sohail S, Alam SN. Breast cancer in Pakistan - awareness and early detection. J Coll Physicians Surg Pak 2007;17:711-2.
McInerney NM, Narod S, Metcalfe K, et al. Breast cancer genetics for plastic surgeons. Plast Reconstr Surg 2017;140:455-60.
Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE study group. J Clin Oncol 2004;22:1055-62.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors retain copyright and grant the Journal of Cancer & Allied Specialties (JCAS) right-of-first publication. In addition, the work will be simultaneously licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license. This license allows others to share the work in whole or part (for non-commercial purpose), with an acknowledgement of the work’s authorship and initial publication in JCAS.
Furthermore, authors are free to enter into separate contractual arrangements for the non-exclusive distribution of the journal’s published version of the work, with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to share their work online or in medical or scientific conferences prior to or during submission process.